JP2021513519A5 - - Google Patents
Info
- Publication number
- JP2021513519A5 JP2021513519A5 JP2020541908A JP2020541908A JP2021513519A5 JP 2021513519 A5 JP2021513519 A5 JP 2021513519A5 JP 2020541908 A JP2020541908 A JP 2020541908A JP 2020541908 A JP2020541908 A JP 2020541908A JP 2021513519 A5 JP2021513519 A5 JP 2021513519A5
- Authority
- JP
- Japan
- Prior art keywords
- azabicyclo
- hexane
- amine
- pyridazin
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625656P | 2018-02-02 | 2018-02-02 | |
| US62/625,656 | 2018-02-02 | ||
| PCT/US2019/016300 WO2019152809A1 (en) | 2018-02-02 | 2019-02-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513519A JP2021513519A (ja) | 2021-05-27 |
| JP2021513519A5 true JP2021513519A5 (https=) | 2022-02-16 |
| JP7352294B2 JP7352294B2 (ja) | 2023-09-28 |
Family
ID=67480022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541908A Active JP7352294B2 (ja) | 2018-02-02 | 2019-02-01 | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11414406B2 (https=) |
| EP (1) | EP3746421B1 (https=) |
| JP (1) | JP7352294B2 (https=) |
| KR (1) | KR20200116945A (https=) |
| CN (1) | CN111788182B (https=) |
| AU (1) | AU2019216492A1 (https=) |
| CA (1) | CA3090130A1 (https=) |
| IL (1) | IL276411B2 (https=) |
| WO (1) | WO2019152809A1 (https=) |
| ZA (1) | ZA202004638B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CA3155864A1 (en) * | 2019-10-04 | 2021-04-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| MX2022010634A (es) * | 2020-02-28 | 2023-01-19 | Remix Therapeutics Inc | Derivados de piridazina para modular el empalme de acidos nucleicos. |
| WO2022111500A1 (en) | 2020-11-26 | 2022-06-02 | Rezubio Pharmaceuticals Co., Ltd | Anticholinergic agents |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676444B1 (fr) * | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
| US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| US20040044029A1 (en) | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| DE60225195T2 (de) * | 2002-12-23 | 2009-02-26 | Ranbaxy Laboratories, Ltd. | Flavaxat-derivate als muscarin-rezeptor antagonisten |
| EP1618091A1 (en) | 2003-04-09 | 2006-01-25 | Ranbaxy Laboratories, Ltd. | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2006035280A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
| EP1796667A2 (en) * | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US20080255188A1 (en) | 2005-07-11 | 2008-10-16 | Naresh Kumar | Muscarinic Receptor Antagonists |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| CA2672373C (en) * | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CN101230058A (zh) | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
| CN103102352B (zh) | 2011-11-15 | 2015-08-12 | 山东亨利医药科技有限责任公司 | 酪氨酸激酶抑制剂吲哚满酮衍生物 |
| AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| EP2970200A1 (en) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| JP2017516850A (ja) * | 2014-05-23 | 2017-06-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物 |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| BR112018008630A2 (pt) | 2015-11-06 | 2018-10-30 | Neurocrine Biosciences Inc | derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| EP3416639B1 (en) | 2016-02-16 | 2022-06-08 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US20170355708A1 (en) | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| JP2020530451A (ja) * | 2017-08-08 | 2020-10-22 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| AU2018352828A1 (en) * | 2017-10-17 | 2020-04-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019089676A1 (en) | 2017-10-31 | 2019-05-09 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126559A1 (en) * | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
-
2019
- 2019-02-01 IL IL276411A patent/IL276411B2/en unknown
- 2019-02-01 CN CN201980012827.5A patent/CN111788182B/zh not_active Expired - Fee Related
- 2019-02-01 US US16/966,306 patent/US11414406B2/en active Active
- 2019-02-01 JP JP2020541908A patent/JP7352294B2/ja active Active
- 2019-02-01 CA CA3090130A patent/CA3090130A1/en active Pending
- 2019-02-01 AU AU2019216492A patent/AU2019216492A1/en not_active Abandoned
- 2019-02-01 WO PCT/US2019/016300 patent/WO2019152809A1/en not_active Ceased
- 2019-02-01 KR KR1020207023725A patent/KR20200116945A/ko not_active Ceased
- 2019-02-01 EP EP19747509.8A patent/EP3746421B1/en active Active
-
2020
- 2020-07-27 ZA ZA2020/04638A patent/ZA202004638B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513519A5 (https=) | ||
| JP2023123854A5 (https=) | ||
| AU2019283921A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| TW444013B (en) | Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia | |
| JP2021500345A5 (https=) | ||
| IL273924B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| JP2022520448A5 (https=) | ||
| RU2009136299A (ru) | Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида | |
| JP2017533968A5 (https=) | ||
| JP2009538910A5 (https=) | ||
| JP2023536164A5 (https=) | ||
| JP2016106095A (ja) | イミダゾピロリジノン化合物 | |
| CA2883894A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JPH0219112B2 (https=) | ||
| JP2001524116A (ja) | ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つインドール誘導体 | |
| CN107108588A (zh) | 可用于治疗癌症的稠合双环(杂)芳香族化合物 | |
| CA2611530A1 (en) | Tyrosine kinase inhibitors | |
| CN107207531A (zh) | 作为TGF‑β抑制剂的稠合的咪唑衍生物 | |
| CN104125947A (zh) | 杂环脲化合物 | |
| CN105189497B (zh) | 作为janus激酶抑制剂的n-(2-氰基杂环基)吡唑并吡啶酮 | |
| WO2022140769A1 (en) | Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2 | |
| JP2025504916A5 (https=) | ||
| JP2019537581A5 (https=) | ||
| AU2021299200A1 (en) | Processes for making SERD tricyclic compounds having a substituted phenyl or pyridinyl moiety | |
| JP2023552838A5 (https=) |